View Older Stories View More Recent Stories

Jul 12, 2016 08:00AM Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
Jul 8, 2016 08:00AM Advaxis to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jul 6, 2016 07:02AM Advaxis (ADXS) Granted FDA SPA for Phase 3 Study of AXAL in Patients with Cervical Cancer
Jul 6, 2016 07:00AM FDA Grants Special Protocol Assessment to Advaxis’ Phase 3 Study of AXAL in Patients with Cervical Cancer
Jun 27, 2016 08:00AM Advaxis to Webcast Investor & Analyst Day 2016
Jun 8, 2016 08:05AM Advaxis (ADXS) Doses First Patient in Phase 2 Trial Evaluating AXAL in Anal Cancer
Jun 8, 2016 08:00AM Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer
Jun 6, 2016 07:00AM Advaxis Announces Updated Data at ASCO from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports
May 17, 2016 08:05AM Advaxis to Host Investor & Analyst Day on June 28, 2016
May 5, 2016 09:25AM UPDATE – Advaxis to Present at Jefferies 2016 Healthcare Conference
May 5, 2016 08:35AM Advaxis to Present at Jeffries 2016 Healthcare Conference
Apr 28, 2016 07:06AM Advaxis (ADXS) Receives FDA Fast-Track Designation for ADXS-HER2 in Osteosarcoma
Apr 28, 2016 07:05AM FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma
Apr 25, 2016 08:07AM Advaxis (ADXS) Will Present ADXS11-001 Phase 2 Data at ASCO 2016
Apr 25, 2016 08:05AM Phase II Cervical Cancer Study with Advaxis’ Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting
Apr 19, 2016 09:11AM Advaxis (ADXS) Makes Late-Breaking Presentation of Axalimogene Filolisbac in Head and Neck Cancer at AACR 2016
Apr 19, 2016 09:05AM AACR Research Reception Featured Late-Breaking Poster on Lm Technology™ Platform
Apr 18, 2016 07:11AM Advaxis (ADXS) to Present AXAL Phase 2 Data in HPVOPC at AACR 2016
Apr 18, 2016 07:05AM Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform
Apr 13, 2016 08:00AM Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform
Apr 5, 2016 08:03AM Advaxis (ADXS), Merck (MRK) Complete First Two Dose Escalations in KEYNOTE-046 Trial
Apr 5, 2016 08:00AM Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Apr 4, 2016 09:05AM Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
Mar 29, 2016 07:17AM Advaxis (ADXS) Announces Completion of First Dose-Escalation for AXAL + Durvalumab Combo in HPV-Associated Cancers
Mar 29, 2016 07:05AM Advaxis Combination Trial with MedImmune Completes First Dose-Escalation Cohort
Mar 23, 2016 08:09AM UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
Mar 23, 2016 07:05AM Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
Mar 21, 2016 07:07AM Advaxis (ADXS) Announces Publication of Significant ADXS-HER2 Data in Canine Osteosarcoma
Mar 21, 2016 07:05AM Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
Mar 14, 2016 09:05AM Advaxis to Present at Barclays Global Healthcare Conference
Mar 11, 2016 09:05AM Advaxis (ADXS) COO Mayes Becomes Board Member
Mar 11, 2016 09:05AM Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors
Mar 9, 2016 07:06AM Advaxis (ADXS), SGI-DNA Enter Synthetic DNA Supply Agreement
Mar 9, 2016 07:05AM Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA
Mar 7, 2016 07:05AM Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer
Mar 4, 2016 09:05AM Advaxis to Present at 27th Annual ROTH Conference
Mar 2, 2016 07:05AM Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting
Feb 29, 2016 09:05AM Advaxis to Present at Cowen’s 36th Annual Health Care Conference
Feb 16, 2016 08:05AM Advaxis to Present at 2016 RBC Capital Markets’ Healthcare Conference
Feb 8, 2016 09:05AM Daniel J. O’Connor, President and Chief Executive Officer of Advaxis, Appointed to Board of Trustees of BioNJ
Feb 3, 2016 08:12AM Advaxis (ADXS) Enters ADXS-HPV Tech co-Development, Collaboration with Stendhal
Feb 3, 2016 08:05AM Advaxis’ Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal
Feb 1, 2016 08:05AM Advaxis Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor
Jan 19, 2016 09:05AM Advaxis Expands Intellectual Property for Lm Technology™ Platform
Jan 8, 2016 07:08AM Advaxis (ADXS) Issues Business Outlook for 2016; Will Continue Pursing Immunotherapy Partnerships
Jan 8, 2016 07:05AM Advaxis Provides 2016 Business Outlook
Jan 5, 2016 09:15AM Advaxis Establishes Scientific Advisory Board With Several Distinguished Experts
Dec 16, 2015 09:06AM Advaxis (ADXS) Announces FDA Lifts IND Clinical Hold for Three Product Candidates
Dec 16, 2015 09:05AM FDA Lifts Advaxis Clinical Hold
Dec 14, 2015 09:06AM Advaxis (ADXS) Announces Receipt of EMA Orphan Drug Designation for Axalimogene Filolisbac
View More Recent Stories View Older Stories